Eddingpharm (Cayman)
Kowloon City · Founded 2001
About Eddingpharm (Cayman)
Established in 2001, Eddingpharm’s vision and mission has always been to become China's leading supplier of patented drugs and branded drugs, bridge the gap between Chinese patients and global high quality medicines. They constantly acquired classic branded medicines from MNCs, that benefits Chinese patients through our effective operation cost management and expansion to the low-tier medical terminals. On the other hand, they keep exploring and innovating. Eddingpharm continuously introduce abroad patented drugs to China market, participate in international multi-center clinical trials and strive to realize simultaneous launch of new drugs in China and globally, providing physicians with more treatment options. Over the past few years, they rapidly expanded our business and strategically deployed resources in various fields. They are upgrading to a whole-industry-chain entity from sole in-licensing R&D and commercialization. Eddingpharm has nearly 1,000 professional representatives in 30 provinces across the country, with coverage of 19,000+ hospitals and 20,000+ pharmacies. Over the years, they have collaborated with multinational pharmaceutical companies, specialty pharmaceutical companies and leading R&D institutions to enrich our product portfolio by in-licensing patented drugs, setting up JV, gaining exclusive distribution rights and forming strategic alliances. Our focused therapy areas have been expanded to anti-biology, oncology, respiratory, cardiovascular and renal diseases. In addition, our several new drugs under development or regulatory registration are expected to be launched in the near future. The revolutionary product Vascepa® capsule is a single-molecule prescription product consisting of the icosapentaenoic acid commonly known as EPA in ethyl-ester form. Its ability has been verified that lowering triglyceride levels in relevant patient populations without raising LDL-cholesterol levels. The ability of reducing residual cardiovascular risk in patients with statin-managed LDL-C cholesterol, but persistent elevated triglycerides, has been published in The New England Journal of Medicine in November 2018. Additional results and analysis of total recurrent events observed were subsequently published in the Journal of American College of Cardiology in March 2019. Recently, supplemental new drug application (sNDA) for Vascepa® capsules reducing cardiovascular risks has been accepted for filing and granted Priority Review designation by the US FDA. Eddingpharm has been granted the rights of development, commercialization and supply of VASCEPA® in mainland China, Hong Kong, Macau and Taiwan since 2015, also including the management and sponsor of pivotal clinical trials for registration. They have completed a pharmacokinetic (PK) study in China and a racial comparison study of PK characteristics between Chinese and American healthy subjects. Phase III clinical trial is currently in progress. "Professionalism, excellence, responsibility, and persistence" are the values of Eddingpharm. Our profession is related to life and health, professionalism is the fundamental principle. Excellence runs through every minute of our work. Responsibility is our attitude towards each task. In the face of our beliefs and missions, they will stick to persistence and never give up. They are moving towards the goal that Chinese patients benefit from the world's best medicines and cutting edge medical technology.
Company Facts
- Founded: 2001
- Legal name: Eddingpharm International Holdings Ltd.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 501 – 1,000
- Estimated revenue: $50K – $100K
- Total funding: $44.1M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2010)
- Website: eddingpharm.com
- Phone: +852 37550555
Social Profiles
Canonical: https://fsome.com/organization/eddingpharm-cayman-8441851 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.